• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, October 27, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Insilico collaborates with Teva on AI system for target discovery

Bioengineer by Bioengineer
September 6, 2025
in Health
Reading Time: 1 min read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Insilico enters into a collaboration with Teva to apply novel generative artificial intelligence for the discovery of potential therapeutic targets

Tuesday, June 22, 2021 – Insilico Medicine is pleased to announce that it has entered into a collaboration with Teva Branded Pharmaceutical Products R&D, Inc. to utilize Insilico’s generative machine learning technology and proprietary PandaOmics Drug Discovery Platform, which aims at identifying novel therapeutic targets implicated in a variety of diseases.

“Teva is a global leader in generics and specialty medicines, and we are happy to be contributing to its research and development efforts, especially in the field of novel target discovery,” said Alex Zhavoronkov, PhD, CEO of Insilico Medicine.

PandaOmics is a comprehensive AI-powered platform for novel target discovery integrating over 60 different engines and approaches to target discovery. It provides biologically interpretable insights coupled with business intelligence with multiple experimentally validated case studies.

###

About Insilico Medicine:

Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trial outcomes. Recently, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website http://insilico.com/.

Media Contact
Polly Firs
[email protected]

Tags: AgingBioinformaticsBiotechnologyBusiness/EconomicsCollaborationGerontologyGroup Organization
Share12Tweet8Share2ShareShareShare2

Related Posts

Unlocking Henna’s Healing Power: A Breakthrough Chemical from Lawsonia inermis Fights Fibrosis

October 27, 2025

ACHO: Enhancing Treatment Adherence through Digital Care

October 27, 2025

Decline in Opioid Prescriptions for Pain Management Observed in Canada

October 27, 2025

Canada Struggles to Address Growing Youth Opioid Use Crisis

October 27, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1285 shares
    Share 513 Tweet 321
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    310 shares
    Share 124 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    196 shares
    Share 78 Tweet 49
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    134 shares
    Share 54 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Unlocking Henna’s Healing Power: A Breakthrough Chemical from Lawsonia inermis Fights Fibrosis

ACHO: Enhancing Treatment Adherence through Digital Care

Decline in Opioid Prescriptions for Pain Management Observed in Canada

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.